1311 related articles for article (PubMed ID: 8459049)
1. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
2. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
[TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
4. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
5. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
6. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
[TBL] [Abstract][Full Text] [Related]
7. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.
Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F
Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880
[TBL] [Abstract][Full Text] [Related]
9. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
10. Epitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson's disease Lewy bodies.
Hill WD; Lee VM; Hurtig HI; Murray JM; Trojanowski JQ
J Comp Neurol; 1991 Jul; 309(1):150-60. PubMed ID: 1716646
[TBL] [Abstract][Full Text] [Related]
11. [Incidental occurrence of Lewy bodies in the brains of elderly patients--the relevance to aging and Parkinson's disease].
Wakabayashi K; Takahashi H; Oyanagi K; Ikuta F
No To Shinkei; 1993 Nov; 45(11):1033-8. PubMed ID: 8135950
[TBL] [Abstract][Full Text] [Related]
12. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
15. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH
Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590
[TBL] [Abstract][Full Text] [Related]
16. [The mechanism of Lewy body formation in Parkinson's disease].
Wakabayashi K; Takahashi H
Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
[TBL] [Abstract][Full Text] [Related]
17. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
[TBL] [Abstract][Full Text] [Related]
18. Synphilin-1 is present in Lewy bodies in Parkinson's disease.
Wakabayashi K; Engelender S; Yoshimoto M; Tsuji S; Ross CA; Takahashi H
Ann Neurol; 2000 Apr; 47(4):521-3. PubMed ID: 10762166
[TBL] [Abstract][Full Text] [Related]
19. The neuromythology of Parkinson's Disease.
Calne DB; Mizuno Y
Parkinsonism Relat Disord; 2004 Jul; 10(5):319-22. PubMed ID: 15196512
[TBL] [Abstract][Full Text] [Related]
20. Neuromelanin and Parkinson's disease.
Marsden CD
J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
